Sales and Marketing

Showing 15 posts of 11527 posts found.

NICE rejects Farydak for multiple myeloma

September 16, 2015 Sales and Marketing Farydak, NICE, Novartis, multiple myeloma, panobinostat

NICE has rejected Novartis Farydak in its draft guidance, ruling it out as a treatment for multiple myeloma. Farydak (panobinostat) is …

PureTech appoints Michael MacLean as chief financial officer

September 14, 2015 Medical Communications, Research and Development, Sales and Marketing Michael MacLean, PureTech Health

PureTech Health has appointed Michael MacLean to the management team, as chief financial officer and executive vice president. Michael MacLean …

FDA strengthens safety warning for J&J’s diabetes drug Invokana

September 14, 2015 Sales and Marketing FDA, Food and Drugs Administration, Invokamet, J&J, JJ, Johnson & Johnson, diabetes, invokana, safety warning, type 2 diabetes

Johnson & Johnson has suffered a blow after the FDA strengthened its safety warning for the company’s type 2 diabetes …

Janssen submits EMA application for myeloma drug

September 14, 2015 Sales and Marketing Janssen, daratumumab, multiple myeloma

Janssen has submitted a new marketing authorisation application for European approval of daratumumab for the treatment of patients with relapsed …

Boehringer earns NICE nod for IPF drug Ofev

September 14, 2015 Sales and Marketing Boehringer Ingelheim, IPF, NICE, idiopathic pulmonary fibrosis

NICE has recommended Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis after the German firm agreed to a …

Actelion confirms takeover talks with ZS Pharma

September 11, 2015 Research and Development, Sales and Marketing Actelion, Shire, ZS Pharma, mergers and acquisitions

Swiss drugmaker Actelion has entered discussions with US biotech company ZS Pharma, over a takeover thought to be worth $2.5 …

High Court rules against Pfizer in Lyrica patent case

September 10, 2015 Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, anxiety, epilepsy, generics, neuropathic pain, pregabalin

The High Court of England and Wales today ruled against Pfizer in the patent battle with Actavis on Pfizer’s blockbuster …

Mylan to relaunch $27.1bn hostile takeover of Perrigo

September 10, 2015 Sales and Marketing Mylan Perrigo, acquisitions, hostile bid, mergers, takeover

Mylan is to make yet another hostile $27.1 billion bid for Irish over the counter drug manufacturer Perrigo on Monday, …

New treatment option for ovarian cancer patients in Scotland

September 8, 2015 Medical Communications, Research and Development, Sales and Marketing Roche, Scotland, avastin, ovarian cancer

The Scottish Medicines Consortium (SMC) has approved the use of Avastin in combination with paclitaxel chemotherapy as a treatment for women …

ABPI ‘deeply concerned’ by slow UK drugs uptake

September 7, 2015 Sales and Marketing ABPI, PPRS, Pharmaceutical Price Regulation Scheme, drugs bill, market access, medicines bill

The UK pharma industry paid £209 million to underwrite the UK medicines bill in second quarter of 2015, according to …

NICE recommends Keytruda for advanced skin cancer

September 7, 2015 Research and Development, Sales and Marketing Merck, NICE, keytruda, skin cancer

NICE has approved Merck’s Keytruda (pembrolizumab) as a treatment for advanced skin cancer in final draft guidance for the NHS.  …

Pharma industry to deliver strong growth – despite price pressure

September 7, 2015 Sales and Marketing Moody's, financial ratings, industry, industry growth, pharma, pharma industry

The global pharma industry will buck the trend of growing pricing pressure and deliver strong growth in profits, according to a …

Neurology comes to the fore

September 7, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Alzheimer's disease, multiple sclerosis, neurology

Neurology is an area where pharma has struggled to deliver in recent years.Yet the high unmet need for drugs to …
The Gateway to Local Adoption Series

Latest content